ISRCTN46173989Completed未知
Combination drug treatment in moderate-to-severe essential hypertension
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Department of Health
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients with uncomplicated, moderate-to-severe essential hypertension which is not adequately controlled on triple therapy with amlodipine 5-10 mg once daily (o.d.), enalapril 10-20 mg b.d. and bendrofluazide 5 mg o.d., iv)
Exclusion Criteria
- •Malignant or accelerated hypertension. Serum creatinine >60umol/L, ischaemic heart disease, cerebrovascular disease, impaired liver function, diabetes mellitus, pregnancy or risk of pregnancy, lactation, history of alcoholism, drug abuse or other problems likely to invalidate the informed consent.
Investigators
Similar Trials
Completed
Phase 4
Combination drug therapy for fibromyalgia paiMusculoskeletal DiseasesOther soft tissue disorders, not elsewhere classifiedFibromyalgiaISRCTN20173707Queen's University (Canada)69
Completed
Not Applicable
Combination therapy in rheumatoid arthritisRheumatoid arthritisISRCTN18445519Turku University Hospital (Finland)199
Not yet recruiting
Phase 2
Comparison of outcomes of single drug therapy versus dual drug therapy in the treatment of hemodynamically significant PDACTRI/2024/05/066914Govind Choudhary
Recruiting
Not Applicable
Concurrent Treatment for Patients with Severe Anorexia Nervosa and Post-Traumatic Stress Disorder: A Feasibility Studypost-traumatische stress-stoornisanorexiaanorexia nervosaNL-OMON56517Arkin (Amsterdam)11
Completed
Not Applicable
A clinical study of combination drug against type 2 diabetes - Glubes combination tablets for patients poorly controlled with a-GI or Glinidetype2 diabetesJPRN-UMIN000007203Advanced Clinical Research Organization30